Revolution Medicines, Inc. (RVMD) 

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Show less

Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $0 and sold $12.88M worth of Revolution Medicines, Inc. stock.

On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $20.77M and sold $105.4M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $2.05M was made by Schroeder Thilo (director) on 2023‑03‑10.